Navigation Links
PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Date:6/12/2008

- Data Presented at the 31st European Cystic Fibrosis Conference -

SOUTH PLAINFIELD, N.J. and PRAGUE, Czech Republic, June 12 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced promising new data from two studies of PTC124 in cystic fibrosis (CF). Results from an Israeli Phase 2a extension study evaluating three months of oral PTC124 treatment in adult patients with nonsense-mutation-mediated CF demonstrated statistically significant improvements in the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein and a statistically significant mean [28%] decrease in the frequency of cough, one of the most prominent and burdensome CF-related symptoms. Results from the Hadassah University Hospital in Israel were presented today by Michael Wilschanski, M.D., Director, Pediatric Gastroenterology, and by Eitan Kerem, M.D., principal investigator and head of the Department of Pediatrics and Cystic Fibrosis Center. Separately, results from a European study evaluating 14-day courses of PTC124 in pediatric patients with nonsense-mutation-mediated CF confirmed the CFTR activity observed in previous short-term studies in adult patients. Data from the European study were presented today by Isabelle Sermet-Gaudelus, M.D., Ph.D., principal investigator at l'Hopital Necker-Enfants Malade.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

Patients with CF lack adequate levels of the CFTR protein, a chloride channel that maintains proper hydration of epithelial surfaces in the lung, pancreas, and liver. Patients with nonsense-mutation-mediated CF generally have a severe form of CF because virtually no CFTR protein is produced. Previous studies of PTC124 adult patients with CF evaluated nasal transepithelial potential difference (TEPD) as a surrogate for the presence and activity of the CFTR protein. Across the short- and long-term
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HAMILTON, N.J. , Oct. 22, 2014 ... CLIA-certified, CAP-accredited laboratory which specializes in high ... that it is now offering new Cystic ... including next- generation DNA sequencing platforms. ... a genetically inherited multisystem disorder that affects ...
(Date:10/22/2014)... , Oct 22, 2014 Antigen Discovery ... Irvine, California , announced the receipt of a ... Innovation Research award (SBIR) from the National Institute of Dental and ... the development of a Pan-HIV Protein Microarray Chip, which ... and HIV-2 subtypes and aid in the development of ...
(Date:10/22/2014)... AVACEN Medical announced today that its AVACEN ... clearance by the U.S. Food and Drug Administration. This ... the Internet for: the temporary relief of joint ... and sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... is a sophisticated medical device incorporating over 3,000 firmware ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... International,Inc. (NYSE: BAX ) announced today that ... IX proteins to treat hemophilia B.,Baxter will develop ... of acute bleeding episodes and a chemically modified, ... of bleeding in,hemophilia B patients. Hemophilia B is ...
... Nanoparticles May Deliver Treatments to Human,Organs -, PHILADELPHIA, ... iron-bearing particles to drive healthy cells to,targeted sites in ... to,a new method of delivering cells and genes to ... http://www.newscom.com/cgi-bin/prnh/20080107/DC10966 ), The study team, led by ...
Cached Medicine Technology:Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3Researchers Use Magnetism to Target Cells to Animal Arteries 2Researchers Use Magnetism to Target Cells to Animal Arteries 3Researchers Use Magnetism to Target Cells to Animal Arteries 4
(Date:10/25/2014)... October,s shorter, darker days can trigger a type of ... expert. People affected by seasonal affective disorder, ... and even have trouble getting out of bed. In ... Angelos Halaris, a professor in the department of psychiatry ... of Medicine. "Seasonal affective disorder should not be ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... D.C. (PRWEB) October 22, 2014 With the ... a national survey by the American Institutes for Research (AIR) ... know how to use health insurance, but 42 percent say ... a plan’s details before signing up for coverage. , The ... with only 20 percent able to calculate correctly how much ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4
... told yesterday about a surgeon Dr Jerome Blanchard who had ... only a diseased one. , ,The disciplinary hearing ... the wrong kidney from a patient and left her dependent ... medical notes. Dr Jerome Blanchard took out his patient’s transplant ...
... conclusion drawn by the doctors after treating 65 million ... therapy// to bring the blood pressure to normal range ... ,A number of clinical studies since long has shown ... Professor of Medicine; Brigham and Women’s Hospital and Harward ...
... Dutch study contradicts the popular belief that the effect ... impact on the soldier’s partner and children//. It highlights ... any significant way. ,Psychiatrist Arend Veeninga, in ... no scientific basis to the theory that ‘war trauma ...
... has been found to suppress bladder pain associated with ... is a analog of a metabolite of THC, the ... study presented at the annual meeting of the American ... in the treatment of hypersensitive bladder disorders and similar ...
... its presence in the Indian market and gain wider acceptability, ... punch of health// to its India portfolio, possibly by early ... beverage solutions in the non-alcohol segment. This would include not ... Cola India chief Atul Singh told PTI here. ...
... Manchester feel that Statins, A cholesterol-lowering drug should be prescribed ... reduce the heart diseases. ,The researchers looked at ... the mid-1990s, and recorded how many of them had a ... calculate as to how many people would need to have ...
Cached Medicine News:Health News:Consultant Bungles A Kidney Surgery 2Health News:Combination Drug Therapy For Hypertension 2Health News:Bladder Pain Suppressed By Marijuana-Derived Drug 2Health News:A New Study Feels That The UK heart drug Guidelines Not Enough 2
... sunwear, inspired by modern American ... with long lasting wearability. The ... include sophistication, elegance and enduring ... modern shapes, classic styling and ...
... mounting technology has redefined rimless collections forever.,The ... at the end of each frame mounting. ... the bushing that mounts within the lens. ... secure fit is created that far exceeds ...
... collection celebrates the 85th anniversary of the ... feel, the unmistakable icons that made GUCCI ... and sunglass collection, dedicated to a multifaceted ... design that is the hallmark of the ...
... Whisper NG Erbium YAG Extended Ablation laser ... true laser peel with outstanding results and no ... a proprietary fluence level with an extra long ... skin. Peeling is spread over 3-5 days, ...
Medicine Products: